Pathology News

A modified antibody-RNA therapy gets by the defenses of hard-to-reach and hard-to-treat cancers.

A new study reveals a promising target for reducing amyloid beta buildup and preventing Alzheimer’s disease-like symptoms, such as brain fog, caused by COVID-19.

A new Yale study found that open-source AI tools outperformed traditional, visual methods for measuring the abundance of melanoma biomarkers.

Yale School of Medicine’s Department of Pathology has embraced the booming field of digital pathology, where digital scanners and AI are improving speed and accuracy.

The mid-cycle Blavatnik Accelerator Awards recognize eight Yale early-stage innovations tackling cancer, rare disease, and neurodegeneration through digital platforms, RNA therapies, and next-gen molecules.

In late June, about a dozen members of a Brazilian oncology program, Instituto Oncoclínicas, participated in an international exchange with members of Yale Cancer Center’s multi-disciplinary thoracic cancer program including discussions, presentations, mock and actual tumor board meetings, a tour of Smilow Cancer Hospital and a dinner at Mory's.

Cancer fighting T cells, the immune system’s primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma and those that are present are indifferent to the tumor threat and traditional immune therapies, revealing the need for new targets and treatments.

The inaugural Workshop on Precision Diagnosis of Trophoblastic Disease, hosted by the Center for Precision Medicine of Trophoblastic Disease at Yale (Y-GTD), was a success, according to Pei Hui, MD, PhD, center director.

The second edition of Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology, edited by Pei Hui, MD, PhD, professor of pathology and of obstetrics, gynecology & reproductive sciences at Yale School of Medicine, has been published by Springer. The new edition offers substantial updates to this rapidly evolving field.